November 16, 2011
Gilead Sciences Inc. and Johnson & Johnson's Tibotec division announced Tuesday they will work together to develop a new HIV pill that contains Tibotec's Prezista and Gilead's Emtriva. The tablet also will include Gilead's drug candidates cobicistat and GS 7340, which are not yet approved. Under the arrangement, Gilead will be responsible for manufacturing the drug, handling the regulatory process and selling the medication. Tibotec will retain co-marketing rights in some countries. The companies also partnered to develop Complera, which combines Gilead's Truvada with J&J's Edurant; it was approved in August.
11.15.2011; Associated Press
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.